<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Sculier D</dc:creator>
  <dc:creator>Gayet-Ageron A</dc:creator>
  <dc:creator>Battegay M</dc:creator>
  <dc:creator>Cavassini M</dc:creator>
  <dc:creator>Fehr J</dc:creator>
  <dc:creator>Hirzel C</dc:creator>
  <dc:creator>Schmid P</dc:creator>
  <dc:creator>Bernasconi E</dc:creator>
  <dc:creator>Calmy A</dc:creator>
  <dc:date>2017</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">BACKGROUND
Rilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strategy. It offers the advantages of few drug-drug interactions and a favourable toxicity profile. We aimed to determine the reasons for prescribing the rilpivirine (RPV)/tenofovir disoproxil (TDF)/emtricitabine (FTC) co-formulation within the Swiss HIV Cohort Study and to assess its effectiveness and safety over a 24 months period.


METHODS
All individuals enrolled in the Swiss HIV Cohort Study who initiated a RPV/TDF/FTC co-formulation between April 2013 and March 2014 were included. Primary outcomes were the HIV-RNA viral load (copies/mL) and CD4 cell count (cells/mm3) at 6, 12 and 24 months. Reasons for a switch to RPV/TDF/FTC were evaluated through a standardized questionnaire. We also assessed discontinuation and reasons for discontinuation of RPV/TDF/FTC until October 30, 2015.


RESULTS
Of 644 individuals who started the RPV/TDF/FTC co-formulation, only 7.5% were treatment-naïve. At 24 months, viral suppression (HIV-RNA &lt;50 copies/mL) was achieved in 100% and 96.7% of cART-naïve and cART-experienced patients respectively. The switch to RPV was mainly done for simplification (44.6%) and to overcome central nervous system toxicity symptoms due to efavirenz (24%). Six months after switch, 74.8% of patients reported an improvement of psycho-neurological symptoms with continued improvement at 12 months for almost 80%. However, one quarter of patients reported a discontinuation of RPV/TDF/FTC on October 30, 2015 after a median time of 18.4 months. Reasons for discontinuation included physician decision (5.3%) and side-effects (3.9%) mainly related to the central nervous system and to renal toxicity.


CONCLUSION
The RPV/TDF/FTC co-formulation was safe and effective throughout 24 months of follow-up but barely prescribed for HIV-naïve patients. Despite excellent virological suppression among both treatment-naïve and -experienced patients, we observed a high rate of treatment discontinuation.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/106900</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/s12879-017-2579-2</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28683720</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>BMC infectious diseases. - 2017</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">First-line regimen</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">HIV-1</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Rilpivirine</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Safety</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Treatment simplification</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Virological response</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Adult</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Anti-HIV Agents</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Antiretroviral Therapy, Highly Active</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Benzoxazines</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">CD4 Lymphocyte Count</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Drug Combinations</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Emtricitabine</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">HIV Infections</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">HIV-1</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Middle Aged</dc:subject>
  <dc:subject xmlns:ns20="xml" ns20:lang="en">Prospective Studies</dc:subject>
  <dc:subject xmlns:ns21="xml" ns21:lang="en">Rilpivirine</dc:subject>
  <dc:subject xmlns:ns22="xml" ns22:lang="en">Tenofovir</dc:subject>
  <dc:subject xmlns:ns23="xml" ns23:lang="en">Treatment Outcome</dc:subject>
  <dc:subject xmlns:ns24="xml" ns24:lang="en">Viral Load</dc:subject>
  <dc:title xmlns:ns25="xml" ns25:lang="en">Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
